Congress Weighs Repeal of Tax Credit for Rare Disease Drugs

Long untouchable, the incentive for development of orphan drugs is now a Republican target as lawmakers consider a broad tax overhaul.
By KATIE THOMAS and SHEILA KAPLAN from NYT Health http://ift.tt/2zpkko8
via IFTTT
Drugs (Pharmaceuticals), Federal Taxes (US), Corporate Taxes, Medicine and Health, United States Politics and Government
Source The New York Times
Làm đẹp Blog 247